Salud financiera de hoja de balance de Oncternal Therapeutics

Salud financiera controles de criterios 6/6

Oncternal Therapeutics tiene un patrimonio de los accionistas total de $30.1M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $36.7M y $6.7M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$34.26m
Patrimonio	US$30.05m
Total pasivo	US$6.68m
Activos totales	US$36.73m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($36.1M) de GTU superan a sus pasivos a corto plazo ($5.2M).

Pasivo a largo plazo: Los activos a corto plazo de GTU ($36.1M) superan a sus pasivos a largo plazo ($1.5M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: GTU está libre de deudas.

Reducción de la deuda: GTU no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: GTU tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: GTU dispone de suficiente cash runway para 1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 25.6% cada año.

Salud financiera de hoja de balance de Oncternal Therapeutics

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Oncternal Therapeutics Announces Reverse Stock Split to Bring the Company into Compliance with Nasdaq’s Minimum Bid Price Requirement

Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement

Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement

Recent updates

Oncternal Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science

Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics Announces Reverse Stock Split to Bring the Company into Compliance with Nasdaq’s Minimum Bid Price Requirement

Oncternal Therapeutics, Inc. Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.20 loss in 3Q 2022)

Oncternal Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics, Inc. Adds Matthew Smith to its Prostate Cancer Scientific Advisory Board

New major risk - Financial position

Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement

Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.23 loss in 2Q 2022)

Oncternal Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Oncternal Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Study of ROR1 Targeting Autologous CAR T, ONCT-808, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.20 loss in 1Q 2022)

Full year 2022 earnings released: US$0.84 loss per share (vs US$0.64 loss in FY 2021)

Oncternal Therapeutics, Inc. Appoints Jill DeSimone to the Board of Directors

Oncternal Therapeutics, Inc. Announces the Resignation of Jinzhu Chen from the Board of Directors

Oncternal Therapeutics, Inc. Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.20 loss in 3Q 2021)

Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022

Oncternal Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Oncternal Therapeutics Receives IND Clearance for ONCT-808, Its Autologous Car T Product Candidate Targeting Ror1 for the Treatment of Aggressive B Cell Lymphoma

Oncternal Therapeutics, Inc Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL

Oncternal Therapeutics, Inc. Submitted an Investigational New Drug Application (“IND”) for ONCT-808

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.16 loss in 2Q 2021)

Oncternal Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

High number of new directors

Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in Combination with Ibrutinib for Patients with MCL

Oncternal Therapeutics, Inc. Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib At Asco 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.12 loss in 1Q 2021)

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

High number of new and inexperienced directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oncternal Therapeutics, Inc. Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib At ASH 2021

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.22 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.34 loss in 2Q 2020)

Independent Director Man Cho has left the company

Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib At ASCO 2021

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.31 loss in 1Q 2020)

New 90-day high: €6.95

Revenue beats expectations

Full year 2020 earnings released: US$0.85 loss per share (vs US$3.31 loss in FY 2019)

Oncternal Therapeutics, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day high: €5.45

Oncternal Therapeutics, Inc. Appoints Rosemary Mazanet as a Class I Director

Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from Russell 2000 Dynamic Index

Oncternal Therapeutics, Inc. and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies

Oncternal Therapeutics, Inc. Announces Updated Interim Clinical Data from the Ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib Targeting ROR1 for Leukemia and Lymphoma) Clinical Trial

Oncternal Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $22.500002 million.

Oncternal Therapeutics, Inc. Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting

New 90-day high: €2.90

Third quarter 2020 earnings released: US$0.22 loss per share

New 90-day low: €1.42

Oncternal Therapeutics, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma

New 90-day low: €1.57

Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020

Independent Director recently bought €126k worth of stock

New 90-day low - €1.70

Oncternal Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3.500001 million.

Earnings released

Oncternal Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.151298 million.

Análisis de la situación financiera